Skip to main content

Table 1 directly acting antiviral agent (DAA) regimens and specific indication according to HCV genotype and severity of liver disease

From: Epidemiology and management of hepatitis C virus infections in immigrant populations

DAA regimen

HCV regions covered

HCV Genotype

Pill/day

Duration in weeks

Ombitasvir/paritaprevir/ritonavir/dasabuvir

NS3 + NS5A + NS5B

1,4

4

 

 - Non cirrhosis

   

8a

 - Cirrhosis

   

12

Elbasvir/grazoprevir

NS3 + NS5A

1,4

1

12b

Sofosbuvir/velpatasvir

NS5A + NS5B

1-6

1

12

Glecaprevir/pibrentasvir

NS3 + NS5A

1-6

3

 

 - Non cirrhosis

   

8

 - Cirrhosis

   

12

  1. a genotype 1b; NS3 non-structural 3 region, NS5A non-structural protein 5A, NS5B non-structural protein 5B
  2. b16 weeks for GT1a with high viral load and/or NS5A RASs